Status:
UNKNOWN
18F-LN1 PET/CT in Urothelial Carcinomas
Lead Sponsor:
Sichuan Provincial People's Hospital
Conditions:
Urothelial Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The clinical feasibility of 18F-LN1 PET/CT will be evaluated in 30 patients with urothelial carcinoma, and the results will be compared with those of 18F-FDG.
Detailed Description
This study aims to evaluate the recognition efficiency of 18F-LN1 and 18F-FDG PET imaging for tumor target Nectin-4 in patients with urothelial carcinoma. The main method is to compare the results of ...
Eligibility Criteria
Inclusion
- Age 18 and above
- No gender difference
- Patients who have been diagnosed with, or are clinically highly suspected of, urothelial carcinomas and have had no other treatment within 3 months
Exclusion
- Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg
- Complicated with chronic liver disease, myocardial infarction, stroke
- Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception
- Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06120413
Start Date
November 1 2023
End Date
October 1 2024
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departments of Nuclear Medicine, Sichuan Provincial People's Hospital
Chengdu, Sichuan, China, 610072